Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis

Nuclear Medicine Communications

Volumn 32, Issue 4, 2011, Pages 252-259

  Cheng, Mei Fang ^a   Wu, Yen Wen ^a,b   Liu, Kao Lang ^a   Yen, Ruoh Fang ^a   Wu, Yao Ming ^a   Hsu, Chiun ^a   Chang, Yu Ting ^a   Tzen, Kai Yuan ^a   Wang, Hsiu Po ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Hsin Chu General Hospital   (Taiwan)

Author keywords

18F fluoro 2 deoxy D glucose; dual time point imaging; infiltrative hepatic lesions; positron emission tomography computed tomography; standardized uptake value

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPINE METASTASIS; TREATMENT PLANNING; VIRUS HEPATITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ENDEMIC DISEASE; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; ENDEMIC DISEASES; FEMALE; FLUORODEOXYGLUCOSE F18; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TAIWAN; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952445140     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834368bf     Document Type: Article

References (24)

1. Lee WJ, Lim HK, Jang KM, Kim SH, Lee SJ, Lim JH, et al. Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics 2001; 21:S97-S116.
2. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Riskfactors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology2005; 128:620-626. (Pubitemid 40585364)
3. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341:1368-1378.
4. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16:132-137.
5. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44:540-548. (Pubitemid 39663420)
6. 18F-FDG PETforthe diagnosis and grading ofsofttissue sarcoma: a meta-analysis. J Nucl Med 2003; 44:717-724.
7. 18F-FDG PET in oncology. J Nucl Med 2008; 49:480-508. (Pubitemid 351355215)
8. Cheng MF, Wu YW, Tzen KY, Huang YH, Yen RF. Whole-body F-18 FDG PET for hepatocellular carcinoma patients after interventional treatment. Neoplasma 2007; 54:342-347.
9. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003; 30:1467-1472. (Pubitemid 37356113)
10. 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med 2005; 46:1158-1163. (Pubitemid 43741078)
11. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET/CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008; 103:1145-1151. (Pubitemid 351677961)
12. Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002; 29:1047-1054.
13. Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 2008; 23:759-765. (Pubitemid 351519420)
14. Yen RF, Chen KC, Lee JM, Chang YC, Wang J, Cheng MF, et al. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 2008; 35:1305-1315.
15. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33:1029-1035. (Pubitemid 32378198)
16. Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen W. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2005; 43:358-360. (Pubitemid 40956890)
17. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005; 46:1753-1759. (Pubitemid 46211600)
18. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003; 44: 1407-1412. (Pubitemid 39663352)
19. Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, et al. Staging of peritoneal carcinomatosis: enhanced CTvs. PET/CT. Abdom Imaging 2008; 33:87-93.
20. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206:57-65. (Pubitemid 350267250)
21. Ho CL, Chen S,Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48:902-909. (Pubitemid 46909918)
22. 18F-FDG PET/CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010; 45:560-566.
23. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610-615. (Pubitemid 26111384)
24. Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET/CT. Radiographics 2006; 26:1335-1353. (Pubitemid 44518767)